Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
GLP-1 receptor agonists reduced substance use disorder incidence by 17% compared to SGLT-2 inhibitors in veterans with type 2 diabetes.
This large-scale observational study suggests GLP-1 receptor agonists may influence addiction pathways beyond their established metabolic effects. The finding builds on emerging evidence that GLP-1 signaling affects reward processing in the brain, potentially offering therapeutic benefits for substance use disorders.
This observation could inform prescribing decisions for diabetic patients with substance use risk factors. It also opens a research pathway into GLP-1 therapies for addiction treatment, though the mechanism and reproducibility require validation in controlled trials.
| Study Type | Retrospective Cohort Study |
| Population | 524,817 US veterans with type 2 diabetes, no prior substance use disorders |
| Intervention | GLP-1 receptor agonist initiation (n=124,001) |
| Comparator | SGLT-2 inhibitor initiation (n=400,816) |
| Primary Outcome | Incident substance use disorders (alcohol, cannabis, cocaine, nicotine, opioid, other) |
| Key Finding | 17% reduction in substance use disorder incidence |
| Journal | BMJ |
| Year | 2024 |
Veterans with diabetes who started GLP-1 receptor agonists showed modestly lower rates of developing substance use disorders compared to those starting SGLT-2 inhibitors. This real-world finding warrants consideration when selecting diabetes medications for at-risk patients.
This study cannot establish causation or explain the mechanism behind the association. It does not demonstrate that GLP-1 agonists are effective treatments for existing addiction or that they should be prescribed primarily for substance use prevention.
The observational design cannot control for unmeasured confounders that might influence both medication choice and addiction risk. Veterans may not represent the broader diabetes population, and the study lacks data on cannabis-specific outcomes given federal restrictions.
This large cohort study provides hypothesis-generating evidence that GLP-1 receptor agonists may have protective effects against substance use disorders. While promising, this association requires validation in controlled trials before influencing clinical practice or treatment guidelines.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Can GLP-1 receptor agonists help reduce the risk of developing substance use disorders in diabetic patients?
Yes, this large study of over 500,000 veterans with type 2 diabetes found that GLP-1 receptor agonists reduced the incidence of substance use disorders by 17% compared to SGLT-2 inhibitors. The protective effect was observed across multiple substances including alcohol, cannabis, cocaine, nicotine, and opioids over a three-year follow-up period.
Should I consider GLP-1 agonists specifically for addiction prevention if I have diabetes?
While GLP-1 agonists showed promising results for reducing substance use disorder risk, they should be prescribed primarily for diabetes management with the addiction benefits considered as a potential secondary advantage. The decision should be based on your overall diabetes treatment needs, other medical conditions, and risk factors in consultation with your healthcare provider.
Do GLP-1 receptor agonists help patients who already have substance use disorders?
The study included a protocol examining patients with pre-existing substance use disorders, though specific outcomes for this group were not detailed in the summary provided. The primary evidence focuses on preventing new substance use disorders rather than treating existing ones.
How does this finding affect cannabis use specifically in diabetic patients?
Cannabis use disorder was among the substance use disorders that showed reduced incidence with GLP-1 receptor agonist use in this study. This suggests that diabetic patients taking GLP-1 agonists may be less likely to develop problematic cannabis use patterns compared to those on other diabetes medications like SGLT-2 inhibitors.
Is this protective effect against substance use disorders seen with all diabetes medications?
No, this protective effect appears specific to GLP-1 receptor agonists when compared to SGLT-2 inhibitors in this study. The comparison was made between these two specific drug classes, suggesting that the anti-addictive properties may be unique to GLP-1 agonists rather than a general effect of diabetes treatment.
